Houston Methodist

Platform Technologies for Rapid Response Biological Countermeasures

The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants has sparked concern over the continued effectiveness of existing vaccines and therapeutic antibodies. Together with increased genomic surveillance, methods to rapidly develop and assess effective interventions are critically needed. We recently developed methods to
characterize spike mutations emerging in variants of concern (VOCs) using mammalian synthetic biology and developed technologies for the rapid discovery of potent SARS-CoV-2 neutralizing antibodies from previously infected patients. These strategies should prove broadly applicable in interrogating adaptive immunity and in developing rapid-response biological countermeasures to emerging pathogens.

Dial-In Information

This seminar will also be streamed online via MS Teams.

Microsoft Teams meeting

Join on your computer or mobile app

Click here to join the meeting

Or call in (audio only)

+1 832-856-3689,,180306029#   United States, Houston

Phone Conference ID: 180 306 029#

Thursday, June 16 at 12:00pm to 1:00pm

Houston Methodist Research Institute, Ernest H. Cockrell Boardroom R2-311
6670 Bertner Avenue

Event Type

Seminar, Webinar

Attendance Options

In-Person, Livestream Video



Department & Center
Academic Institute, Center for Molecular and Translational Human Infectious Diseases Research

Jimmy D. Gollihar, Jr., PhD, Head of Antibody Discovery & Accelerated Protein Therapeutics (ADAPT), Center for Infectious Diseases, Houston Methodist Research Institute

Contact Email


Google Calendar iCal Outlook